NCT00432094 - Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2006

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

Childhood Germ Cell TumorOvarian CancerTeratoma

Interventions

DRUG

carboplatin

Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes

DRUG

etoposide

600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.

DRUG

ifosfamide

2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.

DRUG

paclitaxel

225 mg/m\^2 intravenous over 3 hours on Day -7.

DRUG

thiotepa

150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4

PROCEDURE

autologous hematopoietic stem cell transplantation

Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)

DRUG

Mesna

2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.

BIOLOGICAL

filgrastim

Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.

Trial Locations (1)

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors

lead

Masonic Cancer Center, University of Minnesota

OTHER